Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P, Schilsky RL, de Leng WWJ, Huitema ADR, Nuijen B, Nederlof PM, van Herpen CML, de Groot DJA, Devriese LA, Hoeben A, de Jonge MJA, Chalabi M, Smit EF, de Langen AJ, Mehra N, Labots M, Kapiteijn E, Sleijfer S, Cuppen E, Verheul HMW, Gelderblom H, Voest EE. van der Velden DL, et al. Among authors: roepman p. Nature. 2019 Oct;574(7776):127-131. doi: 10.1038/s41586-019-1600-x. Epub 2019 Sep 30. Nature. 2019. PMID: 31570881 Clinical Trial.
RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
Radonic T, Geurts-Giele WRR, Samsom KG, Roemen GMJM, von der Thüsen JH, Thunnissen E, Meijssen IC, Sleddens HFBM, Dinjens WNM, Boelens MC, Weijers K, Speel EJM, Finn SP, O'Brien C, van Wezel T, Cohen D, Monkhorst K, Roepman P, Dubbink HJ. Radonic T, et al. Among authors: roepman p. J Thorac Oncol. 2021 May;16(5):798-806. doi: 10.1016/j.jtho.2021.01.1619. Epub 2021 Feb 12. J Thorac Oncol. 2021. PMID: 33588111 Free article.
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar J, Roepman P, de Leng WJ, Jansen AML, van Werkhoven E, van der Noort V, Huitema ADR, Gort EH, de Groot JWB, Kerver ED, de Groot DJ, Erdkamp F, Beerepoot LV, Hendriks MP, Smit EF, van der Graaf WTA, van Herpen CML, Labots M, Hoeben A, Morreau H, Lolkema MP, Cuppen E, Gelderblom H, Verheul HMW, Voest EE. Hoes LR, et al. Among authors: roepman p. Clin Cancer Res. 2022 Apr 1;28(7):1402-1411. doi: 10.1158/1078-0432.CCR-21-3752. Clin Cancer Res. 2022. PMID: 35046062 Free PMC article.
Clinical Impact of Prospective Whole Genome Sequencing in Sarcoma Patients.
Schipper LJ, Monkhorst K, Samsom KG, Bosch LJW, Snaebjornsson P, van Boven H, Roepman P, van der Kolk LE, van Houdt WJ, van der Graaf WTA, Meijer GA, Voest EE. Schipper LJ, et al. Among authors: roepman p. Cancers (Basel). 2022 Jan 16;14(2):436. doi: 10.3390/cancers14020436. Cancers (Basel). 2022. PMID: 35053600 Free PMC article.
Study protocol: Whole genome sequencing Implementation in standard Diagnostics for Every cancer patient (WIDE).
Samsom KG, Bosch LJW, Schipper LJ, Roepman P, de Bruijn E, Hoes LR, Riethorst I, Schoenmaker L, van der Kolk LE, Retèl VP, Frederix GWJ, Buffart TE, van der Hoeven JJM, Voest EE, Cuppen E, Monkhorst K, Meijer GA. Samsom KG, et al. Among authors: roepman p. BMC Med Genomics. 2020 Nov 10;13(1):169. doi: 10.1186/s12920-020-00814-w. BMC Med Genomics. 2020. PMID: 33167975 Free PMC article.
Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics.
Roepman P, de Bruijn E, van Lieshout S, Schoenmaker L, Boelens MC, Dubbink HJ, Geurts-Giele WRR, Groenendijk FH, Huibers MMH, Kranendonk MEG, Roemer MGM, Samsom KG, Steehouwer M, de Leng WWJ, Hoischen A, Ylstra B, Monkhorst K, van der Hoeven JJM, Cuppen E. Roepman P, et al. J Mol Diagn. 2021 Jul;23(7):816-833. doi: 10.1016/j.jmoldx.2021.04.011. Epub 2021 May 6. J Mol Diagn. 2021. PMID: 33964451 Free article.
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. van der Wijngaart H, et al. Among authors: roepman p. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475104
Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
Pruis MA, Groenendijk FH, Badloe KS, van Puffelen A, Robbrecht D, Dinjens WNM, Sleijfer S, Dingemans AC, von der Thüsen JH, Roepman P, Lolkema MP. Pruis MA, et al. Among authors: roepman p. Br J Cancer. 2022 Sep;127(4):776-783. doi: 10.1038/s41416-022-01841-3. Epub 2022 May 23. Br J Cancer. 2022. PMID: 35606463 Free PMC article.
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer.
van Berge Henegouwen JM, Jebbink M, Hoes LR, van der Wijngaart H, Zeverijn LJ, van der Velden DL, Roepman P, de Leng WWJ, Jansen AML, van Werkhoven E, van der Noort V, van der Wekken AJ, de Langen AJ, Voest EE, Verheul HMW, Smit EF, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: roepman p. Eur J Cancer. 2022 Aug;171:114-123. doi: 10.1016/j.ejca.2022.05.009. Epub 2022 Jun 15. Eur J Cancer. 2022. PMID: 35716537 Free article.
64 results